Could a Placenta-Derived powder revolutionize wound healing after skin cancer surgery?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The subject requires Mohs surgery on the scalp, with the resulting wound extending to the subgalea (all subcutaneous fat removed) and a surface area of at least 4cm2. * The subject is willing to complete all follow-up evaluations required by the study protocol. * The subject is to abstain from any other covering or treatment of the wound(s) for the duration of the study unless otherwise directed by the study surgeon or their surrogate * The subject agrees to abstain from enrollment in any other interventional clinical trial for the duration of the study. * The subject and/or guardian is/are able to read and understand instructions and give informed, voluntary, written consent. * The subject is able and willing to follow the protocol requirements. Exclusion Criteria: * The subject's wound site is smaller than 4cm2. * The subject's wound site does not extend to the subgalea. * The subject has invasive melanoma or high-risk squamous cell carcinoma (defined by poor differentiation, presence of perineural invasion) in which the standard of care is to be referred for adjuvant radiation oncology * The subject has a microbiologically proven pre-existing local or systemic bacterial infection. * The subject has been receiving a systemic antibiotic for more than 48 hours prior to grafting. * Unstable cardiac disorders within the past 6 months including angina, abnormal ECG, history of cardiac arrest, surgery and/or other interventional procedure that would preclude the indicated procedure. * Hepatic disease or altered liver function as defined by ALT or AST value \> 3 times the upper limit of normal and/or T. Bilirubin \>1.5 mg/dL at screening. * Renal disease or altered renal function as defined by serum creatinine \> 2 mg/dL at screening, or ESRD. * Hemoglobin \<10.0 or \>19.0 g/dL * Untreated coagulopathy or platelet disorder, or INR \> 1.6, PTT \> 38 sec; PLT \< 50,000 at screening. * The subject is known to have a pre-existing, chronic condition that, in the opinion of the Investigator, may interfere with complete re-epithelialization including but not limited to untreated malignancy, uncontrolled diabetes (HbA1c \>10), autoimmune disease or other immunocompromised diseases, hematological diseases, peripheral artery diseases, and /or malnourishment with an albumin \< 2.5. * The subject currently uses illicit substances or has drug or alcohol dependency. * The subject is unable to follow the protocol. * The subject is taking medication known to have an effect on wound healing or skin pigmentation within 30 days prior to surgery (e.g. corticosteroids, retinoids etc.) * The subject has a known hypersensitivity to Compound Sodium Lactate for Irrigation (Hartmann's) solution. * The subject is pregnant or lactating or intends to become pregnant during the study. * The subject has other concurrent conditions that in the opinion of the investigator may compromise patient safety or study objectives.